{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T19:59:00Z","timestamp":1785268740055,"version":"3.55.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,28]]},"DOI":"10.7759\/cureus.113529","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T19:03:30Z","timestamp":1785265410000},"source":"Crossref","is-referenced-by-count":0,"title":["Preventing Type 2 Diabetes in At-Risk Cardiorenal Populations"],"prefix":"10.7759","author":[{"given":"Diego","family":"de Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achille","family":"Peiris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele CE","year":"2023","unstructured":"Ndumele CE, Rangaswami J, Chow SL, et al.. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation. 2023, 148:1606-35. 10.1161\/CIR.0000000000001184","journal-title":"Circulation"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001186","article-title":"A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association","volume":"148","author":"Ndumele CE","year":"2023","unstructured":"Ndumele CE, Neeland IJ, Tuttle KR, et al.. A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association. Circulation. 2023, 148:1636-64. 10.1161\/CIR.0000000000001186","journal-title":"Circulation"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2026.03.056","article-title":"2026 AHA\/ACC\/ADA\/ASN guideline for the prevention, detection, evaluation, and management of cardiovascular-kidney-metabolic syndrome: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"87","author":"Ndumele CE","year":"2026","unstructured":"Ndumele CE, Rodriguez F, Dixon DL, et al.. 2026 AHA\/ACC\/ADA\/ASN guideline for the prevention, detection, evaluation, and management of cardiovascular-kidney-metabolic syndrome: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2026, 87:e1889-2007. 10.1016\/j.jacc.2026.03.056","journal-title":"J Am Coll Cardiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/1756-0500-7-415","article-title":"Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging","volume":"7","author":"Bailey RA","year":"2014","unstructured":"Bailey RA, Wang Y, Zhu V, Rupnow MF. Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging. BMC Res Notes. 2014, 7:415. 10.1186\/1756-0500-7-415","journal-title":"BMC Res Notes"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","unstructured":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024, 105.S117-314. 10.1016\/j.kint.2023.10.018","journal-title":"Kidney Int"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris GL","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, et al.. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020, 383:2219-29. 10.1056\/NEJMoa2025845","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-42989-z","article-title":"SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients with CKD: a systematic review and meta-analysis","volume":"13","author":"Mavrakanas TA","year":"2023","unstructured":"Mavrakanas TA, Tsoukas MA, Brophy JM, Sharma A, Gariani K. SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients with CKD: a systematic review and meta-analysis. Sci Rep. 2023, 13:15922. 10.1038\/s41598-023-42989-z","journal-title":"Sci Rep"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington WG","year":"2023","unstructured":"Herrington WG, Staplin N, Wanner C, et al.. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023, 388:117-27. 10.1056\/NEJMoa2204233","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler WC","year":"2002","unstructured":"Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002, 346:393-403. 10.1056\/NEJMoa012512","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(25)00022-1","article-title":"Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial","volume":"13","author":"Knowler WC","year":"2025","unstructured":"Knowler WC, Doherty L, Edelstein SL, et al.. Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial. Lancet Diabetes Endocrinol. 2025, 13:469-81. 10.1016\/S2213-8587(25)00022-1","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2337\/dc26-S003","article-title":"Prevention or delay of diabetes and associated comorbidities: Standards of Care in Diabetes-2026","volume":"49","year":"2026","unstructured":"Prevention or delay of diabetes and associated comorbidities. Standards of Care in Diabetes-2026. Diabetes Care. 2026, 49:S50-60. 10.2337\/dc26-S003","journal-title":"Diabetes Care"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic V","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al.. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019, 380:2295-306. 10.1056\/NEJMoa1811744","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink HJ","year":"2020","unstructured":"Heerspink HJ, Stef\u00e1nsson BV, Correa-Rotter R, et al.. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020, 383:1436-46. 10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.100927","article-title":"Comparative effectiveness of sodium-glucose cotransporter-2 (SGLT2) inhibitors versus glucagon-like peptide-1 (GLP-1) agonists on cardiovascular and renal outcomes in type 2 diabetes: a systematic review and network meta-analysis","volume":"18","author":"Alqurain AA","year":"2026","unstructured":"Alqurain AA, Salem M, Algarzai BA, et al.. Comparative effectiveness of sodium-glucose cotransporter-2 (SGLT2) inhibitors versus glucagon-like peptide-1 (GLP-1) agonists on cardiovascular and renal outcomes in type 2 diabetes: a systematic review and network meta-analysis. Cureus. 2026, 18:e100927. 10.7759\/cureus.100927","journal-title":"Cureus"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2337\/dc26-S002","article-title":"Diagnosis and classification of diabetes: Standards of Care in Diabetes-2026","volume":"49","year":"2026","unstructured":"Diagnosis and classification of diabetes. Standards of Care in Diabetes-2026. Diabetes Care. 2026, 49:S27-49. 10.2337\/dc26-S002","journal-title":"Diabetes Care"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2337\/dc26-S011","article-title":"Chronic kidney disease and risk management: Standards of Care in Diabetes-2026","volume":"49","year":"2026","unstructured":"Chronic kidney disease and risk management. Standards of Care in Diabetes-2026. Diabetes Care. 2026, 49:S246-60. 10.2337\/dc26-S011","journal-title":"Diabetes Care"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/516451-preventing-type-2-diabetes-in-at-risk-cardiorenal-populations","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T19:03:31Z","timestamp":1785265411000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/516451-preventing-type-2-diabetes-in-at-risk-cardiorenal-populations"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.113529","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,28]]}}}